Compare Alcon AG (ALC) vs Danaos Corporation (DAC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Danaos Corporation — how do they compare? Alcon AG trades at $66.81 (market cap $32.69B), while Danaos Corporation trades at $126.58 (market cap $2.27B). The key difference: Alcon AG is far larger — about 14.4× Danaos Corporation's market cap, and Danaos Corporation pays the higher dividend (2.88%). Which is the better fit depends on your goals.
| ALC | DAC | |
|---|---|---|
Market Cap | $32.69B | $2.27B |
Sector | Health | Technology |
52-Week High | $92.22 | $134.63 |
52-Week Low | $62.02 | $84.05 |
Enterprise Value | $36.28B | $2.28B |
Dividend Yield | 0.54% | 2.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Danaos Corporation (DAC) trades at $125.34, up 2.47% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 4.42 and net income margin near 50%, supported by consistent dividend payments. Recent earnings beat expectations in two of the last three quarters, with Q2 2026 results pending.
Outlook remains positive due to deep value metrics and robust cash flow, but risks include cyclical shipping demand and capital expenditure pressures. Analyst sentiment is mixed with 40% buy ratings, suggesting cautious optimism amid solid operational performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Danaos Corporation
Danaos is a leading international owner of containerships, providing seaborne transportation services globally. It charters its fleet of vessels to major shipping lines across Asia, Europe, and the Americas.
Read more on DAC →
